A Comparative, Dose-Escalating, Placebo-Controlled Study of the Efficacy and Safety of PAZ320, Ingested Together With a Standard Meal on Post-Prandial Glucose and Insulin Blood Levels in Type II Diabetic Patients Treated With Metformin
Latest Information Update: 07 Nov 2021
At a glance
- Drugs BTI 320 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boston Therapeutics
- 30 Sep 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 09 Oct 2014 Study stated to be ongoing, according to a Boston Therapeutics media release.
- 12 Nov 2013 Status changed from planning to recruiting. Patient enrolment has begun, according to a Boston Therapeutics media release.